Pneumococcal vaccine and opsonic pneumococcal antibody

Journal of Infection and Chemotherapy

Volumn 19, Issue 3, 2013, Pages 412-425

  Song, Joon Young ^a,c   Moseley, M Allen ^b   Burton, Robert L ^c   Nahm, Moon H ^c,d  

^a Korea University College of Medicine   (South Korea)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c University of Alabama at Birmingham   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Immunogenicity; Opsonophagocytic killing assay; Pneumococcal vaccine; Streptococcus pneumoniae

Indexed keywords

BACTERIUM ANTIBODY; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FICOLIN; MANNOSE BINDING LECTIN; PNEUMOCOCCAL ANTIBODY; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; ANTIGEN RECOGNITION; BACTERIAL VIRULENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLEMENT ACTIVATION; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT RECIPIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; KIDNEY TRANSPLANTATION; OPSONIZATION; OPSONOPHAGOCYTOSIS; PHAGOCYTOSIS; PHAGOSOME; PNEUMOCOCCAL INFECTION; REVIEW; RISK FACTOR; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

EID: 84879227463     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-013-0601-1     Document Type: Review

References (64)

1. WHO. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol Rec. 2007;82:93-104.
2. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893-902.
3. Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29:3398-412.
4. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-502.
5. Avery OT, Dubos R. The protective action of a specific enzyme against type III pneumococcus infection in mice. J Exp Med. 1931;54:73-89.
6. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol. 1995;33:2759-62.
7. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol. 2007;45:1225-33.
8. Robbins JB, Austrian R, Lee CJ, Rastogi SC, Schiffman G, Henrichsen J, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis. 1983;148:1136-59.
9. Shinefield HR, Black S, Ray P, Chang I, Lewis N, Fireman B, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 1999;18(9):757-63.
10. Jodar L, Butler JC, Carlone G, Dagan R, Frasch CE, Goldblatt D, et al. Serological criteria for evaluation and licensure of pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003;21:3265-72.
11. Siber GR, Chang I, Baker S, Fernsten P, O'Brien KL, Santosham M, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25:3816-26.
12. Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol. 2006;13:356-60.
13. Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10:514-9.
14. Park S, Nahm MH. Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun. 2011;79:314-20.
15. Simell B, Nurkka A, Ekstrom N, Givon-Lavi N, Kayhty H, Dagan R. Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine. Clin Vaccine Immunol. 2012;19:1618-23.
16. Parkkali T, Vakevainen M, Kayhty H, Ruutu T, Ruutu P. Opsonophagocytic activity against Streptococcus pneumoniae type 19F in allogeneic BMT recipients before and after vaccination with pneumococcal polysaccharide vaccine. Bone Marrow Transplant. 2001;27:207-11.
17. Shatz DV, Schinsky MF, Pais LB, Romero-Steiner S, Kirton OC, Carlone GM. Immune responses of splenectomized trauma patients to the 23-valent pneumococcal polysaccharide vaccine at 1 versus 7 versus 14 days after splenectomy. J Trauma. 1998;44:760-5.
18. Lee H, Nahm MH, Burton R, Kim KH. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol. 2009;16:376-81.
19. Oishi T, Ishiwada N, Matsubara K, Nishi J, Chang B, Tamura K, et al. Low opsonic activity to the infecting serotype in pediatric patients with invasive pneumococcal disease. Vaccine. 2013;31:845-9.
20. Centers for disease control and prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR Morb Mortal Wkly Rep. 2008;57:144-8.
21. Stuart LM, Ezekowitz RA. Phagocytosis: elegant complexity. Immunity. 2005;22:539-50.
22. Chroneos ZC, Sever-Chroneos Z, Shepherd VL. Pulmonary surfactant: an immunological perspective. Cell Physiol Biochem. 2010;25:13-26.
23. Caron E, Hall A. Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science. 1998;282:1717-21.
24. Hampton MB, Winterbourn CC. Methods for quantifying phagocytosis and bacterial killing by human neutrophils. J Immunol Methods. 1999;232:15-22.
25. Johansson PJ, Sternby E, Ursing B. Septicemia in granulocytopenic patients: a shift in bacterial etiology. Scand J Infect Dis. 1992;24:357-60.
26. 2 levels. J Immunol. 1986;137:3484-7.
27. Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev. 2010;23:740-80.
28. Jansen WT, Gootjes J, Zelle M, Madore DV, Verhoef J, Snippe H, et al. Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies. Clin Diagn Lab Immunol. 1998;5:703-10.
29. Martinez JE, Clutterbuck EA, Li H, Romero-Steiner S, Carlone GM. Evaluation of multiplex flow cytometric opsonophagocytic assays for determination of functional anticapsular antibodies to Streptococcus pneumoniae. Clin Vaccine Immunol. 2006;13:459-66.
30. Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol. 2006;13:165-9.
31. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol. 1997;4:415-22.
32. Fleck RA, Romero-Steiner S, Nahm MH. Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies. Clin Diagn Lab Immunol. 2005;12:19-27.
33. Kim KH, Yu J, Nahm MH. Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol. 2003;10:616-21.
34. Bogaert D, Sluijter M, De Groot R, Hermans PW. Multiplex opsonophagocytosis assay (MOPA): a useful tool for the monitoring of the 7-valent pneumococcal conjugate vaccine. Vaccine. 2004;22:4014-20.
35. Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006;13:1004-9.
36. Burton RL, Nahm MH. Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin Vaccine Immunol. 2012;19:835-41.
37. Nahm MH, Romero-Steiner S. Functional assays for pneumococcal antibody. In: Siber GR, Klugman KP, Makela PH, editors. Pneumococcal vaccines: the impact of conjugate vaccine. Washington, DC: ASM Press; 2008. p. 213-26.
38. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsene JP, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28:S66-76.
39. Kim CH, Kim JS, Cha SH, Kim KN, Kim JD, Lee KY, et al. Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants. Pediatr Infect Dis J. 2011;30:e235-43.
40. Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, Baker S, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192-203.
41. Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126:e493-505.
42. Dagan RPS, Juergens C, Greenberg D, Givon-Lavi N, Gurtman A, Kohberger R, Gruber WC, Scott DA. The efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) additional serotypes on nasopharyngeal colonization: a randomized double-blind pediatric trial. ISPPD-8 Poster #312 2012.
43. Romero-Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AF, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 1999;29:281-8.
44. Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine. 2008;26:5521-6.
45. de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46:1015-23.
46. Scott DA, Komjathy SF, Hu BT, Baker S, Supan LA, Monahan CA, et al. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2007;25:6164-6.
47. Jackson LA, Neuzil KM, Nahm MH, Whitney CG, Yu O, Nelson JC, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide- protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2007;25:4029-37.
48. Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55-70 years of age. Clin Infect Dis. 2009;49:241-8.
49. Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis. 2008;198:1019-27.
50. Frenck RW Jr, Gurtman A, Rubino J, Smith W, van Cleeff M, Jayawardene D, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012;19:1296-303.
51. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis. 2007;7:597-606.
52. Nunes MC, Madhi SA. Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccines Immunother. 2012;8:161-73.
53. Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine. 2001;20:545-53.
54. Fedson DS, Musher DM. Pneumococcal vaccine. In: Plotkin SA, Mortimer EA, editors. Vaccines. 2nd ed. Philadelphia: Saunders; 1994. p. 517-64.
55. Linnemann CC Jr, First MR. Risk of pneumococcal infections in renal transplant patients. JAMA. 1979;241:2619-21.
56. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis. 2003;187:1639-45.
57. Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377-86.
58. Granger R, Walters J, Poole PJ, Lasserson TJ, Mangtani P, Cates CJ, et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;CD001390.
59. Dransfield MT, Harnden S, Burton RL, Albert RK, Bailey WC, Casaburi R, et al. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis. 2012;55:e35-44.
60. Romero-Steiner S, Frasch C, Concepcion N, Goldblatt D, Kayhty H, Vakevainen M, et al. Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol. 2003;10:1019-24.
61. Kamtchoua T, Bologa M, Hopfer R, Neveu D, Hu B, Sheng X, et al. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine. 2013;31:327-33.
62. Lu L, Ma Z, Jokiranta TS, Whitney AR, DeLeo FR, Zhang JR. Species-specific interaction of Streptococcus pneumoniae with human complement factor H. J Immunol. 2008;181:7138-46.
63. Mukerji R, Mirza S, Roche AM, Widener RW, Croney CM, Rhee DK, et al. Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol. 2012;189:5327-35.
64. Musher DM. Editorial commentary: Should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults? Clin Infect Dis. 2012;55:265-7.